CELEX: 62016TA0014
Language: en
Date: 2018-09-11 00:00:00
Title: Case T-14/16: Judgment of the General Court of 11 September 2018 — Apimab Laboratoires and Others v Commission (Consumer protection — Setting of maximum levels for polycyclic aromatic hydrocarbons in food supplements — Regulation (EEC) No 315/93 — Risk analysis — Regulation (EC) No 178/2002 — Manifest error of assessment — Proportionality — Principle of non-discrimination)

22.10.2018   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 381/19
            
         
      Judgment of the General Court of 11 September 2018 — Apimab Laboratoires and Others v Commission
      (Case T-14/16) (1)
      
      ((Consumer protection - Setting of maximum levels for polycyclic aromatic hydrocarbons in food supplements - Regulation (EEC) No 315/93 - Risk analysis - Regulation (EC) No 178/2002 - Manifest error of assessment - Proportionality - Principle of non-discrimination))
      (2018/C 381/20)
      Language of the case: French
      
         Parties
      
      
         Applicants: Apimab Laboratoires (Clermont-l’Hérault, France) and the seven other applicants whose names are listed in the annex to the judgment (represented by: A. de Brosses, lawyer)
      
         Defendant: European Commission (represented by: K. Herbout-Borczak and C. Valero, acting as Agents)
      
         Re:
      
      Action brought under Article 263 TFEU seeking the annulment in part of Commission Regulation (EU) 2015/1933 of 27 October 2015 amending Regulation (EC) No 1881/2006 as regards maximum levels for polycyclic aromatic hydrocarbons in cocoa fibre, banana chips, food supplements, dried herbs and dried spices (OJ 2015 L 282, p. 11).
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Dismisses the action;
               
            
                  2.
               
               
                  Orders Apimab Laboratoires and the other applicants whose names are listed in the annex to bear their own costs and to pay the costs incurred by the European Commission.
               
            
         (1)  OJ C 90, 7.3.2016.